Search Results
Your search for early matches 10130 pages
Showing 6501 - 6550Dana-Farber Cancer Institute, Lifespan Partner to Advance Cancer Treatment and Expand Research
Dana-Farber Cancer Institute and Lifespan—Rhode Island’s first health system—leadership have signed a memorandum of understanding to form a partnership that will advance cancer treatment and expand research. The details will be finalized early next year. “Over the past 6 months, our staff members...
Study Finds Cabozantinib of Clinical Benefit vs Sunitinib in Advanced Renal Cell Carcinoma
A randomized phase II clinical trial evaluating cabozantinib (Cabometyx) compared with standard-of-care sunitinib (Sutent) as first-line therapy for patients with advanced renal cell carcinoma has found that cabozantinib reduced the rate of disease progression or death by 34% compared with...
A Lung Cancer Specialist Talks About Value in Cancer Care
Over the past few years, the term value-based cancer care has become integrated into the vernacular of the oncology community. Value is a subjective term, which is defined largely by its clinical setting. However, value in cancer care is evaluated by the multiple stakeholders involved in the...
How Video Support Tools Help Patients Make Informed Decisions About End-of-Life Care
A relatively recent study by Areej El-Jawahri, MD, and her colleagues is showing how the use of visual media can empower patients with advanced cancer, as well as other life-threatening illnesses, to make more informed decisions about their end-of-life care.1 The aim of Dr. El-Jawahri’s study was ...
Adjuvant Sunitinib for Renal Cell Carcinoma: Not Ready for Prime Time
In renal cell carcinoma and other cancer types, a consistent paradigm in drug development exists: Observe efficacy of a drug in the metastatic setting and move quickly to explore the agent in the adjuvant setting. In the cytokine era, there were multiple efforts to characterize whether adjuvant...
Adjuvant Sunitinib Improves Disease-Free Survival in High-Risk Renal Cell Carcinoma After Nephrectomy
In the phase III S-TRAC trial reported at the recent European Society for Medical Oncology meeting and in The New England Journal of Medicine by Alain Ravaud, MD, PhD, of Bordeaux University Hospital, and colleagues, adjuvant sunitinib (Sutent) significantly prolonged disease-free survival vs...
Pembrolizumab in First-Line Treatment of Metastatic Non–Small Cell Lung Cancer
On October 24, 2016, pembrolizumab (Keytruda) was approved for use in patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have high programmed cell death ligand 1 (PD-L1) expression (tumor proportion score ≥ 50%) as determined by a U.S. Food and Drug Administration...
Locally Advanced Esophageal Cancer Outcomes Improved With Neoadjuvant Therapy
In studies presented at the 2016 European Society for Surgical Oncology (ESMO) Congress, two different neoadjuvant treatment approaches improved the outcomes of patients with esophageal cancer. Investigators from the Australasian Gastro-Intestinal Trials Group (AGITG) reported that the addition of...
Clinical Strategies for Improving Endocrine Therapy in Metastatic Breast Cancer
Most women with hormone receptor–positive breast cancer receive endocrine therapy as part of their treatment, but “the reality is that patients who receive antihormone therapy in the metastatic disease setting ultimately develop disease progression, ” William J. Gradishar, MD, stated at the 18th...
Androgen Receptor Antagonists May Meet ‘Unmet Need’ in Triple-Negative Breast Cancer
Although there are no androgen receptor antagonists currently approved for the treatment of breast cancer, clinical trials indicate that these agents benefit some patients with triple-negative breast cancer, Tiffany A. Traina, MD, told participants at the 18th Annual Lynn Sage Breast Cancer...
Association of T-Cell CD62L Expression and Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase CML
Higher baseline levels of T-cell expression of CD62L (L-selectin) were associated with a greater likelihood of molecular response to nilotinib (Tasigna) in early chronic-phase chronic myeloid leukemia (CML), according to a report by Sopper et al in the Journal of Clinical Oncology. The study...
Encouraging First Study of Pembrolizumab in Cutaneous T-Cell Lymphoma
Immunotherapy with an anti–programmed cell death protein 1 (PD-1) inhibitor—pembrolizumab (Keytruda)—showed encouraging responses in patients with advanced cutaneous T-cell lymphoma (either mycosis fungoides or Sézary syndrome). Pembrolizumab achieved a 38% overall response rate and responses...
Apply for ASCO Health Policy Fellowship to Improve Skills Needed to Shape Cancer Policy
ASCO is now accepting applications for its prestigious Health Policy Fellowship, a 1-year fellowship opportunity designed to give early-career oncologists the unique skills necessary to monitor and shape the regulatory and legislative policies that directly affect the practice environment and...
Research Highlights From the 2016 Palliative Care in Oncology Symposium
More than 650 attendees gathered in San Francisco on September 9 and 10 for the 2016 Palliative Care in Oncology Symposium, focusing on the theme of “Patient-Centered Care Across the Cancer Continuum.” Research presented during the Symposium demonstrated how integrating palliative care into cancer...
Prospective Cutaneous Lymphoma International Prognostic Index Initiative Moves Forward
A collaboration of international experts is tackling the challenges involved in understanding and managing the treatment of cutaneous lymphomas. The Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study from the Cutaneous Lymphoma International Consortium brings together...
Adult Survivors of Childhood Cancers Report Long-Term Health Issues
Although progress in treatment and supportive care for children with cancer has resulted in improved survival of these patients, some survivors experience ongoing medical conditions from their cancer or its treatment, including poor general health, poor mental health, functional impairment,...
Updated ASTRO Guideline Expands Pool of Suitable Candidates for Accelerated Partial-Breast Irradiation
On November 17, the American Society for Radiation Oncology (ASTRO) issued an updated clinical practice statement for accelerated partial-breast irradiation for early-stage breast cancer. The updated guideline reflects recent evidence that greater numbers of patients can benefit from accelerated...
High-Throughput Sequencing of T-Cell Receptors May Transform Diagnosis and Treatment of Cutaneous T-Cell Lymphomas
High-throughput sequencing of T-cell receptors may be a solution to some of the challenges confronting oncologists who treat cutaneous T-cell lymphomas. According to experts who presented talks on high-throughput sequencing of T-cell receptors at the 3rd World Congress of Cutaneous Lymphoma...
Fulminant, Fatal Myocarditis Reported in Two Patients After Starting Combined Immune Checkpoint Blockade Treatment
In an article in The New England Journal of Medicine, Johnson et al reported the occurrence of fulminant, fatal immune-related myocarditis in two patients who received combined ipilimumab (Yervoy) and nivolumab (Opdivo) for metastatic melanoma. Patient Courses One patient was a 65-year-old woman...
Expert Point of View: Paul Baas, MD, PhD
Invited discussant Paul Baas, MD, PhD, of The Netherlands Cancer Institute, Amsterdam, first commented on the need for measures to improve outcomes in early-stage non–small cell lung cancer (NSCLC). “Even in stage I patients, we still have a failure rate of 30% to 40% at 5 years, and that...
Practices Provided Concrete Path Toward Alternative Payment System
Earlier this month, ASCO announced it has collaborated with Innovative Oncology Business Solutions, Inc (IOBS) to launch ASCO COME HOME, a patient-centered oncology medical home, to help transition community oncology practices from volume-based care to value-based care and to prepare oncologists to ...
Neoadjuvant Nivolumab Appears Safe and Feasible in Lung Cancer
Neoadjuvant immunotherapy with the programmed cell death protein 1 (PD-1) inhibitor nivolumab (Opdivo) is safe and feasible in early-stage non–small cell lung cancer (NSCLC). The results come from the first report of PD-1 blockade prior to surgery in this tumor, according to Patrick Forde, MD, of...
The Emergence of Philanthropy to Fund High-Risk, High-Reward Cancer Research
Earlier this year, Sean Parker, the cofounder of the music streaming service Napster and an early president of Facebook, joined a growing list of entrepreneurs who are committing large portions of their wealth to funding cancer research. In April, Mr. Parker announced he was donating $250 million...
Vaccine Therapy in Metastatic Renal Cell Carcinoma: Past, Present, and Future
As reviewed in this issue of The ASCO Post, Brian Rini, MD, and colleagues recently reported results from the phase III IMPRINT trial,1 which randomized HLA-A*02–positive patients with treatment-naive metastatic clear cell variant renal cell carcinoma, in favorable- and intermediate- risk...
Neoadjuvant Chemotherapy in High-Risk Soft-Tissue Sarcoma: A New Standard?
For the first time, a randomized trial has provided good evidence to support the use of neoadjuvant chemotherapy for treatment of high-risk soft-tissue sarcoma of the extremities or trunk wall.1 But the findings of the study were surprising, because neoadjuvant chemotherapy with one-size-fits-all...
‘Breakthrough’ in Recurrent Ovarian Cancer: Niraparib Extends Progression-Free Survival in Platinum-Sensitive Disease
A landmark study showed that the investigational PARP (poly ADP-ribose polymerase) 1/2 inhibitor niraparib, when used as maintenance therapy, significantly improves the outcome of platinum-sensitive recurrent ovarian cancer. Specifically, niraparib significantly prolonged progression-free survival ...
Recent Progress and Concepts in Pancreatic Cancer
November is National Pancreatic Cancer Awareness Month, the impetus for this article. Pancreatic cancer is a huge health challenge. It's the eighth most common cancer in the United States and the fourth most common cause of cancer deaths but is expected to become the second most common cause of...
Another Step Forward for Genomic Assays in Early-Stage Breast Cancer: Findings With MammaPrint in the MINDACT Trial
Genomic assays have had a powerful influence on the management of early-stage breast cancer, particularly estrogen receptor–positive tumors. The mainstay of adjuvant treatment for early-stage, hormone receptor–positive breast cancer has been endocrine therapy, either with tamoxifen and an...
Pembrolizumab as First-Line Therapy in Metastatic NSCLC: Practice-Changing Implications of KEYNOTE-024 Trial
We are in the midst of a paradigm shift in lung cancer. In the past 2 years, the anti–programmed cell death protein 1 (anti–PD-1) inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda) were found to improve overall survival in the second-line setting compared with docetaxel for patients with...
Pembrolizumab Improves Outcomes vs Platinum-Based Chemotherapy in Advanced PD-L1–Positive NSCLC
In the phase III KEYNOTE-024 trial reported in The New England Journal of Medicine by Martin Reck, MD, PhD, of the German Center of Lung Research, Grosshansdorf, and colleagues, pembrolizumab (Keytruda) significantly improved progression-free and overall survival vs platinum-based chemotherapy in...
Update on Neoplastic Hematology: Review of Recent Clinical Trials
Here is a brief look at the study findings and clinical implications of several recent and important clinical trials in neoplastic hematology. Attention is focused on myelodysplastic syndromes, multiple myeloma, and chronic lymphocytic leukemia. Myelodysplastic Syndromes Clinical Trial:...
SITC 2016: Interim Phase I/II Data Show Encouraging Clinical Benefit for Lirilumab in Combination With Nivolumab in Head and Neck Cancer
An interim efficacy analysis from a phase I/II study of the combination of lirilumab and nivolumab (Opdivo) in the cohort of advanced platinum refractory squamous cell carcinoma of the head and neck, including exploratory biomarker analyses of patient response by level of programmed death ligand 1...
Factors in Clonal Evolution of Chemotherapy-Resistant Urothelial Carcinoma Identified
Faltas et al identified factors in the clonal evolution of chemotherapy-resistant urothelial carcinoma, according to a study reported in Nature Genetics. Findings included wide intrapatient mutational heterogeneity and enrichment for clonal mutations involving L1 cell–adhesion molecule...
SITC 2016: Immune Checkpoint Inhibitors Shrink Tumors in Some Patients With Metastatic Bladder Cancer
Combination immunotherapy is producing response rates ranging from 26% to 38% among patients with metastatic bladder cancer in the early stages of a three-arm clinical trial presented at the 2016 Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, Maryland. “Until...
Enrollment Disparity in National Lung Cancer Trials
Pang et al found that the enrollment disparity in clinical trials in lung cancer has been reduced in recent years for older patients and women overall, according to a study reported in the Journal of Clinical Oncology. However, disparities persist for elderly women, blacks, Asian/Pacific Islanders, ...
Impact of Neoadjuvant Therapy on Survival in Resectable Pancreatic Cancer
In a propensity score–matched analysis of National Cancer Database data reported in the Journal of Clinical Oncology, Mokdad et al found that neoadjuvant therapy followed by resection was associated with a survival benefit vs upfront resection. Patricio M. Polanco, MD, of the Division of Surgical...
Prevalence of Early Endocrine Disorders in Survivors of Childhood Brain Tumors
Clement et al found that 25% of survivors of childhood brain tumors were diagnosed with endocrine disorders over 6.6 years of follow-up, based on a Dutch nationwide study reported in the Journal of Clinical Oncology. Hanneke M. van Santen, MD, PhD, of Wilhelmina Children’s Hospital, University...
Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients
In the HIV-negative population, there is growing evidence suggesting that chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) are both associated with the development of non-Hodgkin lymphoma (NHL), although the mechanisms underlying this association remain unclear. The incidence rate of NHL ...
Higher Baseline Metabolic Tumor Volume and Poorer Outcomes in Patients With High Tumor Burden Follicular Lymphoma
In a pooled analysis reported in the Journal of Clinical Oncology, Michel Meignan, MD, PhD, of the Université Paris-Est Créteil, and colleagues found that higher baseline total metabolic tumor volume measured by 18F-fluorodeoxyglucose (18F-FDG) positron-emission tomography–computed tomography (FDG...
Expect Questions About Medical Marijuana
“Whether or not individual professionals support the clinical use of herbal cannabis, all clinicians will encounter patients who elect to use it and therefore need to be prepared to advise them on cannabis-related clinical issues despite limited evidence to guide care,” according to a recently...
When Marijuana Was Legal in the United States
Marijuana, or cannabis, used to be legal in the United States and was “actually listed in the U.S. formulary in 1854,” according to Judith A. Paice, PhD, RN, Director, Cancer Pain Program, Division of Hematology-Oncology at Northwestern University, Feinberg School of Medicine, Chicago. “Many of...
Medical Marijuana: The Topic You Can’t Escape
With reports about new marijuana dispensaries sprouting up as more states approve the legal use of medical marijuana, and patients and family members questioning how to get it, medical marijuana is a “topic you can’t escape,” noted Judith A. Paice, PhD, RN.1 Dr. Paice is Director of the Cancer...
The Smartest Guys in the Room
The smartest guys in the room were never from the big energy companies, and they’re not running hedge funds on Wall Street or building the next Facebook. For me, the smartest guys in the room are the selfless men and women who’ve transformed cancer from what was all too often a death sentence to...
New Blood Test for Colorectal Cancer Recurrence: Twice as Sensitive as CEA Test
In a new report published by Young et al in Cancer Medicine,1 a two-gene circulating tumor DNA (ctDNA) blood test for postsurgical monitoring of colorectal cancer recurrence has been shown to detect twice the number of recurrence cases as carcinoembryonic antigen (CEA) testing, a standard-of-care...
Development and Validation of a Quality Assurance Score for Robot-Assisted Radical Cystectomy
What are the factors that add up to the best outcomes for patients who have surgery to treat cancer? Looking for a better way to measure quality of care and share best practices in surgical oncology, a team from Roswell Park Cancer Institute developed a quality assessment tool and validated it in a ...
Talking to Children With Cancer: Sometimes Less Is More
I still remember the day I met Kensie. It was Valentine’s Day. I had sneaked out of the hospital to get my wife a Valentine’s Day card, taking my place among scores of other husbands and boyfriends in front of the rapidly emptying rack of cards. As I started browsing, my beeper sounded. It was the ...
Forging Collaboration Between Children’s and Adult Oncology Groups in Designing Trials for Adolescents and Young Adults
Nonrhabdomyosarcoma soft-tissue sarcomas account for about 5% of all childhood malignancies and are also diagnosed in adolescents and young adults, as well as in older adults, and can require different approaches to treatment based on a patient’s age and stage of disease. These sarcomas comprise...
Dana-Farber Cancer Institute, CPDC at McMaster University Join to Speed Cancer Research With Molecular Probes
Dana-Farber Cancer Institute and the Centre for Probe Development and Commercialization (CPDC) at McMaster University in Hamilton, Ontario, Canada, will work together to create novel molecular probes for noninvasive imaging in cancer research, drug development, and patient care. The two leading...
Cardio-oncology in the Geriatric Patient
As cancer therapies improve and the population as a whole increases, there are rising numbers of elderly patients with cancer. More than half of patients newly diagnosed with cancer are aged 65 years or older.1 In January 2012, it was estimated that more than 8 million cancer survivors were over...
ASCO Introduces Two New Journals: JCO Precision Oncology and JCO Clinical Cancer Informatics
ASCO is excited to launch two new online-only journals, JCO Precision Oncology (JCO PO) and JCO Clinical Cancer Informatics (JCO CCI). Both journals will be exploring the latest topics in oncology and filling a void for the oncology community. Manuscripts will go through the traditional peer-review ...
